Pharmacogenomics of preterm birth prevention and treatment
- PMID: 26542879
- PMCID: PMC4729635
- DOI: 10.1111/1471-0528.13744
Pharmacogenomics of preterm birth prevention and treatment
Abstract
Pharmacogenomics and personalised medicine incorporate genetic factors, historical data, and environmental exposures to predict individual variation in response to medications. The study of pharmacology and pharmacogenomics is challenging in obstetrics, and our knowledge in this area lags behind other disciplines of medicine. Some preliminary data, however, suggest that some of the interindividual variation seen in response to medications given for the prevention (progesterone) and the treatment (nifedipine, terbutaline, and others) of preterm labour may be caused by pharmacogenomic effects. A comprehensive approach, integrating clinical data, environmental factors, including concomitant medications and genotype, to optimise the prevention and treatment strategies for preterm birth, is urgently needed.
Tweetable abstract: Some of the variation to meds for prematurity prevention/treatment may arise from pharmacogenomic effects.
Keywords: Personalised medicine; pharmacogenomics; prematurity prevention; preterm birth; progesterone; tocolysis.
© 2015 Royal College of Obstetricians and Gynaecologists.
Figures
References
-
- Shastry BS. Pharmacogenetics and the concept of individualized medicine. Pharmacogenomics J. 2006;6(1):16–21. - PubMed
-
- Khan LM. Comparative epidemiology of hospital-acquired adverse drug reactions in adults and children and their impact on cost and hospital stay--a systematic review. Eur J Clin Pharmacol. 2013;69(12):1985–1996. - PubMed
-
- Trusheim MR, Berndt ER, Douglas FL. Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nat Rev Drug Discov. 2007;6(4):287–293. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
